| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +100.00% | -7.35% | -0.35% | -7.00% | -6.58% | — |
| 14d | 3 | +100.00% | -8.08% | -1.14% | -6.94% | -4.60% | — |
| 30d | 3 | +66.67% | -4.44% | +0.74% | -5.18% | -3.09% | — |
| 60d | 3 | +66.67% | -7.17% | +4.23% | -11.41% | -14.16% | — |
| 90d | 3 | +100.00% | -19.17% | +2.63% | -21.80% | -22.29% | — |
| 180d | 3(1 pending) | +100.00% | -31.68% | +7.51% | -39.19% | -39.19% | — |
| 1y | 3(3 pending) | — | — | — | — | — | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 23,588 | $3.58 | $84.5K | 2,175,796 | Jun 5, 2026 | Jun 5, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE CEO and President | 62,701 | $3.04 | $190.6K | 2,199,384 | May 15, 2026 | Mar 18, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 28,298 | $3.35 | $94.7K | 2,262,085 | Mar 9, 2026 | Mar 11, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE CEO and President | 14,280 | $3.49 | $49.8K | 2,290,383 | Feb 17, 2026 | Feb 19, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 30,346 | — | — | 2,315,027 | Feb 6, 2026 | Feb 10, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE CEO and President | 10,364 | $3.98 | $41.2K | 2,304,663 | Feb 6, 2026 | Feb 10, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 1,673,546 | — | — | 2,284,681 | Feb 6, 2026 | Feb 10, 2026 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 124,403 | $4.41 | $548.6K | 611,135 | Dec 22, 2025 | Dec 29, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE Chief R&D Commercial Officer | 17,584 | $4.14 | $72.8K | 735,538 | Nov 17, 2025 | Nov 19, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 169,851 | — | — | 169,851 | Nov 5, 2025 | Nov 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 84,925 | — | — | 753,122 | Nov 5, 2025 | Nov 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE Chief R&D Commercial Officer | 36,599 | $5.52 | $202.2K | 668,197 | Aug 18, 2025 | Aug 19, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE Chief R&D Commercial Officer | 3,789 | $5.64 | $21.4K | 704,796 | Aug 15, 2025 | Aug 19, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE Chief R&D Commercial Officer | 3,796 | $4.25 | $16.1K | 708,585 | May 15, 2025 | May 19, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 420,226 | — | — | 420,226 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 210,113 | — | — | 707,085 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 8,049 | — | — | 715,134 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | SALE Chief R&D Commercial Officer | 2,753 | $7.25 | $20.0K | 712,381 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 496,972 | — | — | 496,972 | Aug 1, 2024 | Aug 5, 2024 ↗ | View → |
| RXRX RECURSION PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 993,944 | — | — | 993,944 | Aug 1, 2024 | Aug 5, 2024 ↗ | View → |